Table 3.

Treatment-related adverse events reported by ≥20% of patients or in grade 3 or more severity in each dose level

Fostamatinib Dosea:	50 mg (n = 10)		100 mg (n = 15)		150 mg (n = 5)		200 mg (n = 7)
Adverse event, n (%):	All grades	Grade ≥3	All grades	Grade ≥3	All grades	Grade ≥3	All grades	Grade ≥3
Anemia	4 (40)	0	2 (13)	0	4 (80)	1 (20)	2 (29)	0
Leukopenia	3 (30)	0	2 (13)	0	4 (80)	0	4 (57)	0
Neutropenia	0	0	0	0	1 (20)	0	1 (14)	0
Thrombocytopenia	1 (10)	0	2 (13)	0	0	0	2 (29)	0
Lymphopenia	6 (60)	0	5 (33)	0	3 (60)	1 (20)	5 (71)	1 (14)
Diarrhea	1 (10)	0	0	0	2 (40)	0	1 (14)	0
Nausea	2 (20)	0	4 (27)	0	1 (20)	0	0	0
Fatigue	4 (40)	0	2 (13)	0	1 (20)	0	1 (14)	0
Hair loss	0	0	0	0	1 (20)	0	0	0
Diaphoresis	0	0	0	0	1 (20)	0	0	0
Hypertension	2 (20)	0	3 (20)	0	2 (40)	1 (20)	3 (43)	2 (29)
Thrombosis/embolismb	0	0	2 (13)	2 (13)	0	0	0	0
Proteinuriab	0	0	1 (7)	0	0	0	0	0
Elevated AST	3 (30)	1 (10)	4 (27)	0	4 (80)	0	5 (71)	1 (14)
Elevated ALT	4 (40)	1 (10)	4 (27)	0	2 (40)	0	5 (71)	0
Elevated ALP	1 (10)	1 (10)	2 (13)	0	1 (20)	0	3 (43)	2 (29)
Hyperbilirubinemia	3 (30)	0	1 (7)	1 (7)	2 (40)	1 (20)	3 (43)	1 (14)
Hypophosphatemia	2 (20)	0	0	0	1 (20)	0	0	0
Hypocalcemia	0	0	0	0	2 (40)	0	0	0
Hypokalemia	0	0	0	0	2 (40)	0	0	0
Hyperkalemia	0	0	0	0	1 (20)	0	0	0
Hypomagnesemia	0	0	0	0	1 (20)	0	0	0
Hypercholesterolemia	0	0	0	0	1 (20)	0	0	0
Elevated CK	0	0	1 (7)	0	1 (20)	0	0	0

AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; CK, creatine kinase.

^aOne dosage of Fostamatinib; i.e., “50” means Fostamatinib twice a day continuously.

^bIncluded due to clinical relevance.